Asset Details
Do you wish to reserve the book?
Norwegian society of rheumatology recommendations on diagnosis and treatment of patients with giant cell arteritis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Norwegian society of rheumatology recommendations on diagnosis and treatment of patients with giant cell arteritis
Do you wish to request the book?
Norwegian society of rheumatology recommendations on diagnosis and treatment of patients with giant cell arteritis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Norwegian society of rheumatology recommendations on diagnosis and treatment of patients with giant cell arteritis
2023
Overview
To provide clinical guidance to Norwegian Rheumatologists and other clinicians involved in diagnosing and treating patients with giant cell arteritis (GCA).
The available evidence in the field was reviewed, and the GCA working group wrote draft guidelines. These guidelines were discussed and revised according to standard procedures within the Norwegian Society of Rheumatology. The European Alliance of Associations for Rheumatology (EULAR) recommendations for imaging and treatment in large vessel vasculitis and the British Society for Rheumatology (BSR) guidelines for diagnostics and treatment in GCA informed the development of the current guidelines.
A total of 13 recommendations were developed. Ultrasound is recommended as the primary diagnostic test. In patients with suspected GCA, treatment with high doses of Prednisolone (40-60 mg) should be initiated immediately. For patients with refractory disease or relapse, Methotrexate (MTX) should be used as the first-line adjunctive therapy, followed by tocilizumab (TCZ).
Norwegian recommendations for diagnostics and treatment to improve management and outcome in patients with GCA were developed.
Publisher
Frontiers Media SA,Frontiers Media S.A
We currently cannot retrieve any items related to this title. Kindly check back at a later time.